Table 2.
Baseline Results of Neuropsychometric Test, SF-36 Scores and Laboratory Parameters
| Zinc group (n=35) | Placebo group (n=34) | p-value | |
|---|---|---|---|
| mean ± SD | mean ± SD | ||
| NCT-A, sec | 64.71 ± 19.2 | 71.5 ± 43.3 | 0.41 |
| NCT-B, sec | 152.91 ± 44.7 | 136.68 ± 53.0 | 0.17 |
| SDT, sec | 113.97 ± 30.5 | 105.12 ± 26.6 | 0.2 |
| LTT, sec | 190.6 ± 44.2 | 168.12 ± 47.6 | 0.046 |
| DST, point | 18.74 ± 6.4 | 20.82 ± 8.8 | 0.27 |
| PF | 65.86 ± 12.5 | 65.56 ± 16.9 | 0.93 |
| SF | 77.63 ± 18.8 | 78.88 ± 20.9 | 0.79 |
| MH | 65.6 ± 16.2 | 69.53 ± 17.8 | 0.34 |
| BP | 59.83 ± 18.8 | 63.85 ± 26.8 | 0.47 |
| PH | 52.43 ± 20.1 | 51.62 ± 18.4 | 0.86 |
| RP | 57.86 ± 40.1 | 54.41 ± 42.4 | 0.73 |
| RM | 52.17 ± 37.5 | 52.94 ± 45.1 | 0.94 |
| VT | 57.94 ± 16.2 | 58.24 ± 18.9 | 0.95 |
| SF-36 | 489.31 ± 125.4 | 495.03 ± 160.1 | 0.87 |
| ALT, U/L | 44.51 ± 28.1 | 56.03 ± 35.9 | 0.14 |
| Albumin, g/dL | 4.03 ± 0.5 | 4.03 ± 0.6 | 0.97 |
| Platelets x 103 | 161.4 ± 78.3 | 145.1 ± 71.9 | 0.37 |
| INR | 1.1 ± 0.1 | 1.18 ± 0.2 | 0.06 |
| Zinc, mcg/dL | 68.47 ± 20.6 | 68.65 ± 16.7 | 0.97 |
| Ammonia, µmol/L | 89.1 ± 61.2 | 95.99 ± 58.1 | 0.63 |
| MELD | 9 ± 3.1 | 9.15 ± 2.5 | 0.83 |
| CTP | 5.17 ± 0.5 | 5.32 ± 0.6 | 0.28 |
Value presented as mean ± SD and n (%) in NP test and laboratory. And presented as median (IQR) in SF-36 test. P-value corresponds to Independent t and Fisher’s exact test. NCT-A, number connection test part A; NCT-B, number connection test part B; DST, digit symbol test; SDT, serial dotting test; LTT, line tracing test; MELD, Model for End-Stage Liver Disease; CTP, Child-Turcotte-Pugh; PF, physical functioning; SF, social functioning; MH, mental health; BP, bodily pain; PH, perception in health; RP, role-physical; RE, role emotional; VT, vitality